NYSE$LH

Laboratory Corp Of America Holdings · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Labcorp's first quarter of 2021 showed strong financial performance, driven by revenue growth in both Diagnostics and Drug Development segments.

Labcorp announced strong Q1 2021 results with revenue increasing by 47.4% to $4.16 billion and adjusted EPS rising to $8.79. The company raised its full-year guidance, reflecting improved recovery in the base businesses and sustained COVID-19 testing contributions.

  • Revenue for Q1 2021 was $4.2 billion, up from $2.8 billion last year.
  • Diluted EPS for Q1 2021 was $7.82, a significant increase from ($3.27) last year.
  • Adjusted EPS for Q1 2021 was $8.79, up from $2.37 last year.
  • Free Cash Flow for Q1 2021 was $1.1 billion, compared to $97 million last year.

Headline financials

Total Revenue

$4.16B

Previous: $2.82B+47.4%
EPS (adj)

$8.79

Previous: $2.37+270.9%
TTM Book-to-Bill

1.47

Previous: 1.26+16.7%
Capital Expenditures

-$95.4M

Previous: -$107M+10.5%
Free Cash Flow

$674M

Previous: -$424M+259.1%
Net Income

$770M

Previous: -$317M+342.6%
Operating Income

$1.06B

Previous: -$193M+649.3%
Gross Profit

$1.6B

Previous: $728M+119.6%
Cash & Equivalents

$1.89B

Previous: $324M+484.3%
Total Assets

$20.4B

Previous: $17.3B+18.0%
Stock-Based Comp

$28.7M

Previous: $17.9M+60.3%

Revenue & EPS history

LabCorp · Revenue · Quarterly

$4.16B

Q1 2021+47.4%vs Q1 2020
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

LabCorp · $2.76B total across 1 segment · Q1 2021

  • Diagnostics Laboratories
    $2.76B+62.2%

Forward guidance

Labcorp raised its 2021 full year guidance to reflect the improved recovery in the Diagnostics and Drug Development base businesses, while the COVID-19 Testing contribution remains within the original guidance range provided.

Tailwinds

  • Revenue raised to 2.0% to 6.5%
  • Adjusted EPS raised to $20.00 to $24.00
  • Free Cash Flow raised to $1.8 billion to $2.0 billion

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-0.3%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-0.9%

Avg return

30 days after

48%

35 / 73 earnings

Positive

+9.5%

Q2 2024

Best reaction

-10.4%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.0%+0.0%+1.3%
Q4 2025-2.1%+0.0%-6.6%
Q3 2025-5.7%-7.9%-2.7%
Q2 2025-0.5%+1.2%+2.0%
Q1 2025+4.7%+7.9%+7.5%
Q4 2024-0.9%-1.9%+1.2%
Q3 2024+4.0%+3.7%+9.0%
Q2 2024+9.5%+4.8%+6.7%
Q1 2024-4.6%-3.2%-4.0%
Q4 2023-5.0%-5.5%-8.3%
Q3 2023+0.6%+1.0%+7.6%
Q2 2023-1.9%-2.4%-3.0%
Q1 2023-4.6%-2.5%-8.2%
Q4 2022+3.2%-0.4%-14.1%
Q3 2022-2.5%-3.2%+5.0%
Q2 2022+5.1%+1.2%-8.1%
Q1 2022-5.0%-3.1%+1.9%
Q4 2021-1.9%-6.0%-5.7%
Q3 2021+2.3%+2.0%+3.1%
Q2 2021+4.6%+6.0%+6.1%
Q1 2021+1.2%+4.1%+4.5%
Q4 2020+4.0%+3.1%+4.1%
Q3 2020+1.0%-1.1%-2.7%
Q2 2020-3.3%-4.2%-13.4%
Q1 2020-6.5%-10.4%-0.4%
Q4 2019+4.1%+1.8%-19.5%
Q3 2019-2.0%-2.3%+0.4%
Q2 2019-6.5%-4.2%-6.9%
Q1 2019+3.7%+6.1%+5.1%
Q4 2018+2.5%+3.8%+3.7%
Q3 2018-7.1%-6.2%-4.1%
Q2 2018-5.4%-6.4%-5.3%
Q1 2018+3.9%+2.8%+9.7%
Q4 2017+3.9%+3.0%+5.9%
Q3 2017+1.7%+2.2%+0.2%
Q2 2017+2.0%+1.3%-1.4%
Q1 2017-4.1%-3.1%-1.9%
Q4 2016+2.4%+2.4%+5.4%
Q3 2016-10.4%-9.4%-7.9%
Q2 2016+0.4%+1.2%-1.4%
Q1 2016+4.1%
Q4 2015+2.8%
Q3 2015+7.8%
Q2 2015+3.8%
Q1 2015-2.7%
Q4 2014+4.9%
Q3 2014+3.5%
Q2 2014-0.5%
Q1 2014-0.7%
Q4 2013+1.1%
Q3 2013-3.2%
Q2 2013+0.0%
Q1 2013+0.7%
Q4 2012-1.7%
Q3 2012-4.0%
Q2 2012-9.0%
Q1 2012-3.4%
Q4 2011+2.2%
Q3 2011-6.6%
Q2 2011-0.6%
Q1 2011+1.4%
Q4 2010-0.2%
Q4 2007-0.2%
Q3 2010+1.6%
Q2 2010+0.9%
Q1 2009+1.8%
Q1 2010+1.6%
Q4 2009-0.4%
Q2 2008-1.6%
Q3 2009-1.6%
Q3 2008-1.6%
Q4 2008-1.4%
Q2 2009-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro